FDA To Companion Dx Developers: Pre-Trial Assay Validation Is Key
This article was originally published in The Gray Sheet
Executive SummaryCompanion diagnostic device makers should ensure their test is analytically validated prior to its use in a drug pivotal trial, FDA stressed at a Sept. 26 meeting at the University of Virginia in Charlottesville.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.